COVID-19 brought the healthcare industry into the spotlight. Healthcare companies' efforts helped the world recover from the crisis, and the pandemic turned out to be a blessing in disguise for several of them.
However, some established companies are not just the beneficiaries of the COVID-19 pandemic. Their strong product portfolio and pipeline make them well-positioned to benefit from the rising chronic diseases, aging population, and increasing healthcare spending. The pharmaceutical market is expected to grow at a 5.9% CAGR to $1.40 trillion by 2026.
